Amendment to Annual Report (Form 10-K/A)

Translational Development Acquisition Corp. (the "Company," "we," "us" or "our") is filing this Amendment No. 1 on Form 10-K/A (this "Amendment") to amend its Annual Report on Form 10-K for the year ended December 31, 2025, originally filed with the Securities and Exchange Commission ("SEC") on March 30, 2026 (the "Original Filing"). Capitalized terms not otherwise defined in this Amendment shall have the same meanings assigned to such terms in the Original Filing.

We are filing this Amendment in response to a comment letter received from the SEC, dated April 30, 2026, in connection with its review of the Original Filing. We are amending and restating in its entirety Part II, Item 9A "Controls and Procedures" in connection with the filing of this Amendment. We have also included in this Amendment, updated certifications by the Company's principal executive officer and principal financial officer under Sections 302 and 906 of the Sarbanes-Oxley Act.

Except as described above, this Amendment does not amend, update or change any other items or disclosures contained in the Original Filing, and accordingly, this Amendment does not reflect or purport to reflect any information or events occurring after the original filing date or modify or update those disclosures affected by subsequent events. Accordingly, this Amendment should be read in conjunction with the Original Filing and the Company's other filings with the SEC.